Close Menu
Home » Parker Foundation Launches $250M Collaborative Institute for Cancer Immunotherapy

Parker Foundation Launches $250M Collaborative Institute for Cancer Immunotherapy

Apr 13, 2016
|
staff reporter

This article has been updated with information from a press conference. 

NEW YORK (GenomeWeb) – The Parker Foundation announced today that it has founded the Parker Institute for Cancer Immunotherapy with a $250 million grant, to bring together six cancer centers that will collaborate to develop immune therapies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Dec
11
Featured Webinar

Advances in Precision Oncology: Tertiary Analysis Software for Solid Tumor NGS

Sponsored by
Roche

This webinar will address how two molecular laboratories are implementing tertiary analysis software to improve their precision oncology workflows.

Dec
17
Featured Webinar

Non-Invasive Characterization of Solid Tumors via NGS Liquid Biopsy Testing

Sponsored by
Thermo Fisher Scientific

This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

Dec
19
Featured Webinar

Evolution of Tumor Profiling in a Clinical Lab: Moving toward Comprehensive Genomic Profiling

Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

What's Popular?

In Cancer

  1. Roche Ending Partnership With Syapse

  2. Adaptive Biotechnologies, AbbVie Partner on MRD Testing in Multiple Myeloma Drug Trials

  3. Beat AML Umbrella Trial Demonstrates Feasibility of Rapid Precision Medicine Approach

    Premium

  4. ASH Study: Germline Testing Identifies Cancer Risk Mutations, VUS in Older AML Patients

  5. Polygenic Modifiers of Pathogenic Genes May Refine Disease Risk Prediction

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.